Northwestern Mutual Wealth Management CO Biotechnology

Northwestern Mutual Wealth Management CO

$136 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
NVO Novo Nordisk A S	$112B	$12.8 Million 0.01% of portfolio	186,142	Q2 2025 Reduced 53.86%
VRTX Vertex Pharmaceuticals Inc	$99.5B	$5.13 Million 0.0% of portfolio	11,532	Q2 2025 Reduced 11.54%
PTGX Protagonist Therapeutics, Inc	$2.68B	$4.36 Million 0.0% of portfolio	78,894	Q3 2024 Reduced 50.0%
REGN Regeneron Pharmaceuticals, Inc.	$59.7B	$2.01 Million 0.0% of portfolio	3,834	Q2 2025 Reduced 7.23%
BMRN Biomarin Pharmaceutical Inc	$10.6B	$1.49 Million 0.0% of portfolio	27,021	Q2 2025 Added 104.43%
MRNA Moderna, Inc.	$10B	$949,000 0.0% of portfolio	34,399	Q2 2025 Added 34.12%
INCY Incyte Corp	$18.2B	$668,000 0.0% of portfolio	9,816	Q2 2025 Added 15.36%
IONS Ionis Pharmaceuticals Inc	$5.85B	$483,000 0.0% of portfolio	12,244	Q2 2025 Reduced 0.92%
CRSP Crispr Therapeutics Ag	$4.42B	$358,000 0.0% of portfolio	7,380	Q2 2025 Added 7.38%
RPRX Royalty Pharma PLC	$15.7B	$357,000 0.0% of portfolio	9,928	Q2 2025 Added 30.2%
JAZZ Jazz Pharmaceuticals PLC	$7.1B	$294,000 0.0% of portfolio	2,775	Q2 2025 Reduced 19.19%
TGTX Tg Therapeutics, Inc.	$3.94B	$254,000 0.0% of portfolio	7,084	Q2 2025 Reduced 11.73%
ALNY Alnylam Pharmaceuticals, Inc.	$52.9B	$161,000 0.0% of portfolio	496	Q2 2025 Reduced 5.52%
XENE Xenon Pharmaceuticals Inc.	$2.24B	$156,000 0.0% of portfolio	5,000	Q1 2025 Reduced 0.38%
ETON Eton Pharmaceuticals, Inc.	$438M	$142,000 0.0% of portfolio	10,000	Q2 2025 New
UTHR United Therapeutics Corp	$13.7B	$127,000 0.0% of portfolio	443	Q2 2025 Added 18.77%
AVXL Anavex Life Sciences Corp.	$840M	$120,000 0.0% of portfolio	13,047	Q2 2025 Reduced 12.27%
BPMC Blueprint Medicines Corp	$7.73B	$108,000 0.0% of portfolio	850	Q2 2025 Reduced 2.19%
RNXT Renovo Rx, Inc.	$9.97M	$98,000 0.0% of portfolio	74,596	Q2 2025 New
TECH Bio Techne Corp	$2.07B	$95,000 0.0% of portfolio	1,863	Q2 2025 Reduced 4.12%
VCEL Vericel Corp	$1.72B	$86,000 0.0% of portfolio	2,039	Q2 2025 Added 1.95%
ARGX Argenx Se	$35.3B	$73,000 0.0% of portfolio	133	Q2 2025 Added 60.24%
PTCT Ptc Therapeutics, Inc.	$3.24B	$70,000 0.0% of portfolio	1,453	Q3 2023 Reduced 1.82%
CUE Cue Biopharma, Inc.	$28M	$56,000 0.0% of portfolio	83,000	Q2 2025 Added 730.0%
VKTX Viking Therapeutics, Inc.	$3.06B	$55,000 0.0% of portfolio	2,109	Q2 2025 Added 29.55%
BCRX Biocryst Pharmaceuticals Inc	$1.55B	$54,000 0.0% of portfolio	6,127	Q1 2025 Reduced 30.9%
NTLA Intellia Therapeutics, Inc.	$825M	$47,000 0.0% of portfolio	5,110	Q2 2025 Added 11.33%
AXSM Axsome Therapeutics, Inc.	$4.51B	$42,000 0.0% of portfolio	406	Q2 2025 Added 6.28%
OCGN Ocugen, Inc.	$223M	$38,000 0.0% of portfolio	40,001	Q2 2025 Added 0.0%
MNKD Mannkind Corp	$942M	$29,000 0.0% of portfolio	7,836	Q4 2024 New
VCYT Veracyte, Inc.	$2.06B	$27,000 0.0% of portfolio	1,003	Q2 2025 Added 0.3%
BNTX Bio N Tech Se	$26.9B	$22,000 0.0% of portfolio	209	Q2 2025 Reduced 4.57%
HALO Halozyme Therapeutics, Inc.	$8.95B	$22,000 0.0% of portfolio	440	Q2 2025 Reduced 0.68%
XERS Xeris Biopharma Holdings, Inc.	$992M	$13,000 0.0% of portfolio	2,789	Q1 2025 New
APLS Apellis Pharmaceuticals, Inc.	$2.63B	$10,000 0.0% of portfolio	600	Q2 2025 Reduced 0.99%
EYPT Eye Point Pharmaceuticals, Inc.	$366M	$9,000 0.0% of portfolio	1,000	Q1 2024 New
BBIO Bridge Bio Pharma, Inc.	$7.28B	$8,000 0.0% of portfolio	208	Q2 2025 New
PCVX Vaxcyte, Inc.	$1.78B	$8,000 0.0% of portfolio	264	Q2 2025 Reduced 41.33%
ZLAB Zai Lab LTD	$3.36B	$8,000 0.0% of portfolio	231	Q2 2025 New
CYTK Cytokinetics Inc	$3.23B	$7,000 0.0% of portfolio	224	Q2 2025 Added 244.62%
LGND Ligand Pharmaceuticals Inc	$2.58B	$7,000 0.0% of portfolio	63	Q2 2025 Reduced 68.5%
BGNE Bei Gene, Ltd.	$23.5B	$6,000 0.0% of portfolio	29	Q2 2025 Reduced 6.45%
MDXG Mimedx Group, Inc.	$821M	$6,000 0.0% of portfolio	1,000	Q3 2024 Reduced 50.0%
CGTX Cognition Therapeutics Inc	$25M	$5,000 0.0% of portfolio	16,767	Q2 2025 Added 155.32%
CHRS Coherus Bio Sciences, Inc.	$71.5M	$5,000 0.0% of portfolio	7,385	Q2 2025 Reduced 25.03%
RARE Ultragenyx Pharmaceutical Inc.	$1.97B	$5,000 0.0% of portfolio	156	Q2 2025 Added 194.34%
ARWR Arrowhead Pharmaceuticals, Inc.	$1.88B	$3,000 0.0% of portfolio	234	Q1 2025 Reduced 88.21%
CPRX Catalyst Pharmaceuticals, Inc.	$2.09B	$3,000 0.0% of portfolio	146	Q2 2025 New
IOVA Iovance Biotherapeutics, Inc.	$352M	$3,000 0.0% of portfolio	1,880	Q2 2025 Reduced 34.72%
ORMP Oramed Pharmaceuticals Inc.	$81.5M	$3,000 0.0% of portfolio	1,575	Q3 2022 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northwestern Mutual Wealth Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Northwestern Mutual Wealth Management CO with notifications on news.